The US Food and Drug Administration’s approval of two new vaccines places the spotlight on what would normally be a routine next step on the road to market, the US Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), as questions swirl about administrative disruption and vaccine skepticism at the top levels of the Trump Administration.
GSK’s Penmenvy, Bavarian Nordic’s Vimkunya Clear US FDA, Will CDC Follow?
The US FDA approval of new meningococcal and chikungunya vaccines arrived in time for the 26-28 February meeting of the CDC’s Advisory Committee On Immunization Practices, if political developments allow.
